With the acquisition of Vigene Biosciences, a leading contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions, we further strengthened our ability to support our clients with end-to-end cell and gene therapy support

Vigene has significant expertise in CGMP viral vector manufacturing of adeno-associated viruses (AAV), the most commonly used delivery solution for gene therapies, as well as other major viral vectors, including lentivirus, retrovirus and adenovirus. Vigene also specializes in producing high-quality, research grade, and CGMP plasmid DNA, a fundamental tool used in the development of viral vectors for gene-modified cell therapies, gene therapies, and vaccine production.

With operations based in Rockville, MD, Vigene expands and complements our viral vector and plasmid DNA offerings in Europe (with the acquisition of Cobra Biologics). When combined with our integrated portfolio of Biologics Testing Solutions, we now offer a comprehensive solution from discovery and non-clinical development through CGMP manufacturing in advanced drug modalities.